MAP2K7 and melanoma: Several drugs were identified and ranked based on their potential to disrupt this signaling network; notably alisertib, a highly specific inhibitor of AURKA, which has been previously reported for its beneficial effect in combination with BRAF and MEK inhibitors in melanoma treatment (40, 49).